focus -WSS

focus

author：comprehensive 2025-09-28 01:16:54 - browse：4

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

WSS

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

One Duchenne patient's bittersweet hope for new treatment

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

White House finalizes ITC's import ban of latest Apple Watches

Antibiotic resistance and the global rise in human conflict

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

entertainment

focus

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Grail's uphill battle for Medicare to cover its cancer screening test

Psychedelics group wrestles with new pharma identity

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Medical leaders decry Supreme Court decision on affirmative action

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Drug repurposing or repositioning? The language matters

JPM: CVS says Medicare Advantage patients are impacting profits

Malaria cases in Florida and Texas: Here’s what you need to know

How are insurers handling Leqembi and related scans?

hotspot

Inflation cooled significantly in June, bringing price hikes close to normal levels

The biotech scorecard for Q1: 17 stock

Morgan Health, with ambitious aims, wants you to know it’s still here

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

AdventHealth escalates lawsuit against insurance vendor Multiplan

knowledge

entertainment

Wikipedia

explore